WO2025012900 - GENETICALLY ENGINEERED MUCOSAL-ASSOCIATED INVARIANT T (MAIT) CELLS FOR ADOPTIVE TRANSFER CELLTHERAPY
National phase entry is expected:
Publication Number
WO/2025/012900
Publication Date
16.01.2025
International Application No.
PCT/IL2024/050670
International Filing Date
09.07.2024
Title **
[English]
GENETICALLY ENGINEERED MUCOSAL-ASSOCIATED INVARIANT T (MAIT) CELLS FOR ADOPTIVE TRANSFER CELLTHERAPY
[French]
CELLULES T INVARIANTES ASSOCIÉES AUX MUQUEUSES (MAIT) GÉNÉTIQUEMENT MODIFIÉES POUR THÉRAPIE CELLULAIRE PAR TRANSFERT ADOPTIF
Applicants **
PLURI BIOTECH LTD.
MATAM PARK
BUILDING 05
3508409 HAIFA, IL
HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
JERUSALEM BIOPARK
HADASSAH EIN KEREM MEDICAL CENTER
P.O.BOX 12000
9112001 JERUSALEM, IL
Inventors
MACHLENKIN, Arthur
BEN GEFEN 80
7044730 GEDERA, IL
LOTEM, Michal
SDEROT HAOMARIN
MODIIN-MACABIM-REUT, IL
SHAKED, Helena Lea
HASHALOM 20
4356120 RAANANA, IL
KLEIN SILBERMAN, Shira
6 KARKOM STREET
APT. 4
MODIIN, IL
Priority Data
63/525,836
10.07.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
ILPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2445 | |
| EPO | Filing, Examination | 16857 | |
| Japan | Filing | 595 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 9960 |
Total: 30432 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure relates in general to the field of genetic engineering of immune cells, specifically to mucosal-associated invariant T (MAIT) cells genetically engineered to express an exogeneous T cell receptor (TCR) and uses thereof. More specifically, the invention in embodiments thereof relates to cell compositions adapted for adoptive transfer cell therapy (ACT) providing for improved therapeutic modalities.[French]
La présente invention concerne en général le domaine de l'ingénierie génétique de cellules immunitaires, en particulier des cellules T invariantes associées aux muqueuses (MAIT) génétiquement modifiées pour exprimer un récepteur de lymphocytes T (TCR) exogène et leurs utilisations. Plus spécifiquement, l'invention concerne, dans certains modes de réalisation, des compositions cellulaires conçues pour une thérapie cellulaire par transfert adoptif (ACT) permettant d'obtenir des modalités thérapeutiques améliorées.